No Need to Abandon Focused Unilateral Exploration for Primary Hyperparathyroidism with Intraoperative Monitoring of Intact Parathyroid Hormone

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism in this clinical trial publication.

The researchers investigated the rate of persistent and recurrent hyperparathyroidism after focused unilateral exploration (UE) with intraoperative monitoring of intact parathyroid hormone (IOPTH).

Who Took Part

According to the abstract, 915 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

A prospective cohort of 915 patients with primary hyperparathyroidism (PHP) underwent parathyroid surgery by a single surgeon from January 2003 to September 2013.

A total of 556 patients with at least a single positive preoperative localization by ultrasound (US) and/or sestamibi scan (STS) underwent UE with IOPTH.

What Was Measured

The subject headings attached to it are Biomarkers, Hyperparathyroidism, Primary, Monitoring, Intraoperative, Parathyroid Hormone, Parathyroidectomy, Recurrence and Reoperation.

What This Means in Plain Language

This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 915 patients in people with hyperparathyroidism.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Journal of the American College of Surgeons), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.